Welcome to our dedicated page for Davita SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DaVita Inc. (NYSE: DVA) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its kidney care operations, capital structure and governance. This page aggregates those SEC filings and pairs them with AI-powered tools to help readers understand the implications for the company’s dialysis and integrated kidney care business.
For DaVita, current reports on Form 8-K are particularly informative. Recent 8-K filings describe quarterly financial results, including consolidated revenues, operating income, cash flow and key U.S. dialysis metrics, as well as board actions such as increases to the company’s share repurchase authorization. Other 8-Ks outline material definitive agreements, including amendments to DaVita’s senior secured credit facilities that establish new term loan and revolving credit arrangements and explain how proceeds may be used for refinancing, working capital and general corporate purposes.
Investors following DVA can also use SEC filings to track topics such as share repurchases, debt issuance and integrated kidney care strategy. Disclosures around authorization levels for repurchase programs, limitations under credit agreements and the company’s approach to capital allocation appear in these documents. Filings related to financial results provide context on DaVita’s role as a comprehensive kidney care provider, its global network of outpatient dialysis centers and its participation in value-based care models.
On this page, AI-generated summaries highlight the main points of each filing, explain technical language and draw attention to items that may matter to shareholders, such as changes in credit facilities, repurchase authorizations or reported operating performance. Users can quickly locate DaVita’s quarterly and annual reports when available, review Form 8-K disclosures and examine any insider-related filings, while relying on AI assistance to interpret how these regulatory documents relate to the company’s kidney care operations and financial profile.
DaVita Inc. reported a large shareholder transaction involving entities affiliated with Berkshire Hathaway Inc. and Warren E. Buffett. On January 29, 2026, they reported the sale of 1,658,480 shares of DaVita common stock at $120.5561 per share, reported as indirectly owned.
After this sale, they reported indirect beneficial ownership of 30,100,585 DaVita shares. Of this total, 15,126,977 shares are owned by Government Employees Insurance Company, a Berkshire subsidiary. Another 14,973,608 shares are held by pension plans of Berkshire subsidiaries. Berkshire and Mr. Buffett may be deemed beneficial owners but expressly disclaim beneficial ownership except to the extent of any pecuniary interest.
DaVita Inc. filed a current report to announce that it has issued a press release with its financial results for the quarter ended December 31, 2025. The company furnished this earnings release as an exhibit rather than filing it, which limits how it is treated under securities laws.
The report identifies the press release as Exhibit 99.1 and confirms that DaVita’s common stock continues to trade on the New York Stock Exchange under the symbol DVA.
DaVita Inc. reported an insider equity transaction by its Chief Compliance Officer. On 12/04/2025, the officer exercised stock appreciation rights covering 5,875 shares of DaVita common stock at a base price of $108.93 per share, receiving shares instead of cash. On the same date, 5,412 shares of common stock were disposed of at $118.25 per share, and an additional 203 shares were withheld at $118.25 per share to cover tax obligations related to the exercise.
After these transactions, the officer beneficially owned 26,298 shares of DaVita common stock in direct form. The stock appreciation rights used in this exercise were originally granted on March 15, 2021 and vested in two equal installments on March 15, 2024 and March 15, 2025.
DaVita Inc. entered into an Eighth Amendment to its existing Credit Agreement, adding a new five-year secured term loan A facility of up to
Borrowings can be made in U.S. dollars, euros, or pounds sterling, with interest based on benchmark rates such as Term SOFR, EURIBOR, or Daily Simple SONIA plus an Applicable Margin. The initial margin is 150 basis points for benchmark-based loans and 50 basis points for Base Rate loans, with both the margin and the undrawn commitment fee later tied to a leverage ratio grid after financial statements for the quarter ending March 31, 2026 are delivered. The new term loan amortizes quarterly starting March 31, 2026, and proceeds are allocated to repay the prior facilities, pay related fees and expenses, and support working capital and general corporate purposes, including potential stock repurchases, acquisitions, and investments.
DaVita Inc. (DVA) director reports stock acquisition. A director of DaVita Inc. reported acquiring 411 shares of the company’s common stock on 11/15/2025 in a transaction priced at $0 per share, as disclosed on a Form 4. Following this transaction, the director beneficially owns 13,981 shares of DaVita common stock, held directly.
DaVita Inc. director reports a small stock acquisition. A DaVita Inc. (DVA) director filed a Form 4 reporting the acquisition of 411 shares of common stock on 11/15/2025 at a reported price of $0 per share. After this transaction, the director holds 411 shares as a direct owner and 2,894 shares as an indirect owner through the Wendy L. Schoppert Revocable Trust. No derivative securities were reported in this filing.
DaVita Inc. director reports a small stock acquisition. A director of DaVita Inc. (DVA) acquired 411 shares of common stock on 11/15/2025 at a reported price of $0 per share, indicating this was likely an equity grant rather than an open-market purchase. Following this transaction, the director beneficially owns 5,110 shares of DaVita common stock, held directly. No derivative securities such as options or warrants are reported as acquired or disposed of in this filing.
A DaVita Inc. (DVA) director reported acquiring 411 shares of common stock on 11/15/2025 at a stated price of $0, indicating this was likely a stock grant rather than an open-market purchase. Following this transaction, the director beneficially owns 2,089 DaVita shares, held in direct ownership. This is a routine insider ownership update showing a modest increase in the director’s equity stake.
DaVita Inc. director reports stock acquisition
A director of DaVita Inc. (DVA) reported acquiring 411 shares of DaVita common stock on 11/15/2025 in a transaction priced at $0 per share7,231 shares of DaVita common stock in direct ownership. This is a routine insider ownership update, disclosing the director’s latest equity position in the company.
DaVita Inc. director reports small stock acquisition
A director of DaVita Inc. (DVA) reported acquiring 411 shares of DaVita common stock on 11/15/2025 in a Form 4 filing. The shares were acquired at a stated price of $0, which typically indicates an equity award rather than an open-market purchase. Following this transaction, the director now beneficially owns 6,023 shares of DaVita common stock, held directly.